ALT5 Sigma (ALTS) Competitors $8.38 +0.50 (+6.35%) Closing price 07/3/2025 02:49 PM EasternExtended Trading$8.38 0.00 (0.00%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. ANAB, PHAT, TRVI, SANA, IMTX, DAWN, GHRS, ABUS, URGN, and STOKShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include AnaptysBio (ANAB), Phathom Pharmaceuticals (PHAT), Trevi Therapeutics (TRVI), Sana Biotechnology (SANA), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Arbutus Biopharma (ABUS), Urogen Pharma (URGN), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors AnaptysBio Phathom Pharmaceuticals Trevi Therapeutics Sana Biotechnology Immatics Day One Biopharmaceuticals GH Research Arbutus Biopharma Urogen Pharma Stoke Therapeutics AnaptysBio (NASDAQ:ANAB) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings. Does the media prefer ANAB or ALTS? In the previous week, AnaptysBio had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 5 mentions for AnaptysBio and 2 mentions for ALT5 Sigma. AnaptysBio's average media sentiment score of 1.11 beat ALT5 Sigma's score of -0.13 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ANAB or ALTS more profitable? ALT5 Sigma has a net margin of -38.58% compared to AnaptysBio's net margin of -125.70%. ALT5 Sigma's return on equity of -113.79% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-125.70% -282.47% -30.79% ALT5 Sigma -38.58%-113.79%-8.96% Which has more volatility & risk, ANAB or ALTS? AnaptysBio has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Do analysts recommend ANAB or ALTS? AnaptysBio presently has a consensus target price of $42.38, suggesting a potential upside of 76.23%. Given AnaptysBio's stronger consensus rating and higher possible upside, research analysts plainly believe AnaptysBio is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of ANAB or ALTS? 6.3% of ALT5 Sigma shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by company insiders. Comparatively, 4.9% of ALT5 Sigma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, ANAB or ALTS? ALT5 Sigma has lower revenue, but higher earnings than AnaptysBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M7.74-$145.23M-$4.85-4.96ALT5 Sigma$12.53M11.67-$6.24MN/AN/A SummaryAnaptysBio beats ALT5 Sigma on 8 of the 15 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$143.65M$7.54B$12.11B$9.05BDividend YieldN/A4.75%5.54%4.03%P/E RatioN/A18.1320.0220.22Price / Sales11.675.8725.68118.64Price / CashN/A22.1721.6858.07Price / Book17.102.722.285.67Net Income-$6.24M$304.38M$1.00B$249.13M7 Day Performance3.08%6.91%2.21%3.28%1 Month Performance-13.87%13.36%4.59%5.55%1 Year PerformanceN/A24.77%538.58%21.12% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 Sigma0.1269 of 5 stars$8.38+6.3%N/AN/A$143.65M$12.53M0.00170News CoverageANABAnaptysBio2.3406 of 5 stars$23.32+2.2%$42.38+81.7%-3.4%$685.14M$91.28M-4.81100News CoveragePositive NewsInsider TradePHATPhathom Pharmaceuticals3.587 of 5 stars$9.76+3.1%$17.50+79.3%-14.5%$681.35M$55.25M-1.86110TRVITrevi Therapeutics3.2926 of 5 stars$5.77+0.3%$20.29+251.6%+120.8%$676.78MN/A-12.8220News CoverageAnalyst ForecastAnalyst RevisionSANASana Biotechnology2.7835 of 5 stars$2.97+14.2%$9.83+231.1%-38.8%$669.68MN/A-3.38380Analyst ForecastGap UpIMTXImmatics2.4591 of 5 stars$5.44+0.4%$14.67+169.6%-52.3%$661.23M$144.15M-32.00260High Trading VolumeDAWNDay One Biopharmaceuticals1.7556 of 5 stars$6.48flat$30.57+371.8%-49.6%$656.81M$131.16M-9.1360Upcoming EarningsGHRSGH Research1.911 of 5 stars$12.54+7.4%$32.00+155.2%+23.7%$652.46MN/A-15.8710ABUSArbutus Biopharma1.6205 of 5 stars$3.37-1.2%$5.50+63.2%+2.4%$645.46M$6.17M-8.2290URGNUrogen Pharma4.4656 of 5 stars$13.79-3.6%$32.86+138.3%-10.1%$635.86M$90.40M-4.34200High Trading VolumeSTOKStoke Therapeutics4.0327 of 5 stars$11.51-0.7%$23.20+101.6%-9.4%$628.45M$36.56M14.57100Analyst Forecast Related Companies and Tools Related Companies ANAB Alternatives PHAT Alternatives TRVI Alternatives SANA Alternatives IMTX Alternatives DAWN Alternatives GHRS Alternatives ABUS Alternatives URGN Alternatives STOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
